{"id":761222,"date":"2023-06-01T09:05:21","date_gmt":"2023-06-01T13:05:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/"},"modified":"2023-06-01T09:05:21","modified_gmt":"2023-06-01T13:05:21","slug":"revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/","title":{"rendered":"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System"},"content":{"rendered":"

<\/p>\n

Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System<\/b><\/p>\n

The UNIQO 160 allows labs to perform fast, high-quality image capture and analysis to deliver timely, more reliable results<\/i><\/p>\n

WALTHAM, Mass.–(BUSINESS WIRE<\/a>)–Revvity, Inc.<\/a> (NYSE: RVTY), announced today that its EUROIMMUN<\/a> business has launched the UNIQO 160<\/a> (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis.<\/p>\n

\n\u201cTraditional IIFT processing can be tedious and time-consuming, requiring the expertise of specially trained lab technicians and a dark room,\u201d said Dr. Bianca Huth, chief technology officer of EUROIMMUN. \u201cThe design of the UNIQO 160 system and technologies built into it alleviate laboratories of many common challenges by reducing hands-on time and creating efficiencies through end-to-end automation.\u201d<\/p>\n

Automation from Sample to Result<\/b><\/p>\n

\nThe UNIQO 160 integrates a fully automated processing system and high-quality microscope in a single benchtop device that can be seamlessly integrated into existing diagnostics laboratory workflows. Capable of processing 160 primary samples and 18 slides per run, the UNIQO 160 automatically identifies individual samples, reagents and slides loaded into the system by barcode, which ensures a high degree of reliability and traceability of both materials and samples. The UNIQO 160 also covers incubated slides with a mounting medium and a cover glass to protect them from drying out \u2013 an important step to create desirable conditions for subsequent acquisition of high-quality fluorescence images.<\/p>\n

Results Derived from Brilliant Fluorescence Images<\/b><\/p>\n

\nIdeally suited for medium-throughput laboratories, the UNIQO 160 produces brilliant fluorescence images with its optical system\u2019s autofocus feature and three automatically changing objectives (4x, 10x, 20x). Once captured, images are transmitted to the system\u2019s EUROLabOffice 4.0<\/a> middleware for evaluation. The UNIQO 160 system is also compatible with the EUROPattern Classifier, expected to become available later this year. This forthcoming software platform uses state-of-the-art pattern classification based on artificial intelligence methods to aid in final evaluation and propose analytical results.<\/p>\n

Prioritizing Safety and Performance Standards<\/b><\/p>\n

\nIn May 2023, EUROIMMUN received its certificate of compliance with the European In Vitro Diagnostic Medical Device Regulation (EU IVDR). This regulation replaces the previous In Vitro Diagnostic Medical Devices Directive (IVDD) and mandates increased safety and performance requirements for manufacturers of in<\/i>vitro<\/i> diagnostic medical devices offered within the European marketplace. The IVDR-compliant UNIQO 160 has been developed in accordance with these regulatory requirements.<\/p>\n

\nThe UNIQO 160 is the latest addition to EUROIMMUN\u2019s portfolio of automated laboratory solutions, which also includes the EUROPattern Microscope Live<\/a>, EUROLabWorkstation IFA<\/a> and Sprinter XL<\/a> systems. To learn more about these and other EUROIMMUN automated IFA solutions, visit this webpage<\/a>.<\/p>\n

About Revvity<\/b><\/p>\n

\nAt Revvity, \u201cimpossible\u201d is inspiration, and \u201ccan\u2019t be done\u201d is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what\u2019s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.<\/p>\n

\nWith 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.<\/p>\n

\nStay updated by following our Newsroom<\/a>, LinkedIn<\/a>, Twitter<\/a>, YouTube<\/a>, Facebook<\/a> and Instagram<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230601005255\/en\/<\/a><\/span><\/p>\n

Investor Relations:
\n<\/b>
Steve Willoughby
\n
(781) 663-5677
\n
steve.willoughby@revvity.com
\n<\/a><\/p>\n

Media Relations:
\n<\/b>
Chet Murray
\n
(781) 462-5126
\n
chet.murray@revvity.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Medical Devices Health Research Pharmaceutical Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System The UNIQO 160 allows labs to perform fast, high-quality image capture and analysis to deliver timely, more reliable results WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis. \u201cTraditional IIFT processing can be tedious and time-consuming, requiring the expertise of specially trained lab technicians and a dark room,\u201d said Dr. Bianca Huth, chief technology … <\/p>\n

Continue reading “Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-761222","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRevvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System The UNIQO 160 allows labs to perform fast, high-quality image capture and analysis to deliver timely, more reliable results WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis. \u201cTraditional IIFT processing can be tedious and time-consuming, requiring the expertise of specially trained lab technicians and a dark room,\u201d said Dr. Bianca Huth, chief technology … Continue reading "Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-01T13:05:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005255r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System\",\"datePublished\":\"2023-06-01T13:05:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/\"},\"wordCount\":622,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230601005255r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/\",\"name\":\"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230601005255r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-06-01T13:05:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230601005255r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230601005255r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/","og_locale":"en_US","og_type":"article","og_title":"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System - Market Newsdesk","og_description":"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System The UNIQO 160 allows labs to perform fast, high-quality image capture and analysis to deliver timely, more reliable results WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis. \u201cTraditional IIFT processing can be tedious and time-consuming, requiring the expertise of specially trained lab technicians and a dark room,\u201d said Dr. Bianca Huth, chief technology … Continue reading \"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-01T13:05:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005255r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System","datePublished":"2023-06-01T13:05:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/"},"wordCount":622,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005255r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/","name":"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005255r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-06-01T13:05:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005255r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005255r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvitys-euroimmun-spearheads-cutting-edge-diagnostic-analysis-with-new-automated-iift-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revvity\u2019s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/761222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=761222"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/761222\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=761222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=761222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=761222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}